Table 3.
Associations between phthalate biomarker concentrations and ovarian volume (n = 614).
| Phthalate | %Δ (95 % CI) |
|---|---|
| ∑DEHP | 0.22 (−0.45, 0.89) |
| MCPP | −0.44 (−0.02, 0.91) |
| MBzP | 0.62 (0.02, 1.23) |
| MEP | −0.09 (−0.52, 0.35) |
| MBP | −0.23 (−0.98, 0.52) |
| MiBP | −0.49 (−1.23, 0.26) |
| WQSNegative | 0.14 (−1.99, 2.33) |
| WQSPositive | 2.89 (0.27, 5.59) |
Data are presented as the % change (%Δ) in ovarian volume for every 10% increase in phthalate biomarker concentration or every 10% increase in WQS index. All models accounted for race/ethnicity, income, marital status, smoking status, age, oral contraceptive use, change in BMI since age 18, alcohol use, depression symptoms, and reproductive history. WQSNegative and WQSPositive represent findings from WQS regression models with repeated holdouts that were negatively and positively constrained, respectively. CI, confidence interval; ∑DEHP, sum of di(2-ethylhexyl) phthalate metabolites; MBP, monobutyl phthalate; MBzP, monobenzyl phthalate; MCPP, mono(3-carboxypropyl) phthalate; MEP, monoethyl phthalate; MiBP, monoisobutyl phthalate; WQS, Weighted Quantile Sum. Bold indicates meaningful results.